ClinicalTrials.gg
Not yet recruitingNCT06233201Updated Jan 31, 2024

Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator

A Phase 1 interventional study of Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Test product and Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Reference product in Healthy Subjects, sponsored by Bio-innova Co., Ltd. Not yet recruiting. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-31.

Sponsored by Bio-innova Co., Ltd · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose. The study will be randomized, open-label, single dose, two way crossover design with two-period, two-treatment and two-sequence under fed condition and at least 7 days washout period between the doses.

Read the detailed description

Title A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg relative to Originator Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg in healthy Thai volunteers under fed condition.

Objectives The primary objective is to compare the rate and extent of absorption of a generic formulation with that of a reference formulation when given as equal labeled dose. The secondary objective is to evaluate the safety after oral administration of both test and reference formulation in healthy Thai volunteers.

Study Design Randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence under fed condition and at least 7 days washout period between the doses.

Sample Size 34 Healthy Human Thai subjects. Two extra subjects if available, may be checked-in on the day of check in of period-I to compensate for any dropout prior to dosing of period-I. These subjects will be dosed if there are dropouts prior to dosing in period-I. If there are no dropouts, these subjects will be checked-out without being dosed after completion of dosing in period-I.

Drug-Product Test-Product: Sitagliptin and Metformin tablets 50 mg/500 mg Reference-product: Sitagliptin and Metformin tablets 50 mg/500 mg Manufactured by: Patheon Puerto Rico, Puerto Rico 00674

Administration After an overnight fasting at clinical facility of at least 10 hours, each volunteer will receive high fat high calories breakfast which they are required to consume within 30 minutes and then a single dose of Sitagliptin and Metformin tablets 50 mg/500 mg of either test or reference with 250 mL of 20% glucose solution in water within 30 mins after starting the high fat high calories breakfast. Each volunteer will be allowed to drink water as desired except 1 hour before and after drug administration. The formulation is given in a crossover fashion as per the randomization schedule. After the administration, the subject's oral cavity will be checked by using flashlight to confirm complete medication and fluid consumption by pharmacist.

Blood Schedule In each period, a total of 23 blood samples (approximately 5 mL each) will be collected pre-dose (0.00 hour) and at 0.333, 0.667, 1.000, 1.500, 2.000, 2.500, 3.000, 3.333, 3.667, 4.000, 4.333, 4.667, 5.000, 5.500, 6.000, 7.000, 8.000, 10.000, 12.000, 24.000, 36.000 and 48.0000hours after study drug administration, respectively. The sample collection at 24.00, 36.00 and 48.00 hours after dosing will be on ambulatory basis (i.e. on separate visit.).

Sample Collection Blood samples will be collected through an indwelling catheter placed in a vein using disposable syringe or through fresh venipuncture with disposable syringes and needles. Approximately 5mL blood sample will be withdrawn and transferred to sample collection pre-labeled tubes containing K3EDTA as anticoagulant at each sampling time point. After collection of blood samples from each subject at each time point, samples will be centrifuged at 4000 rpm for 5 minutes at 4±2°C. After centrifugation, the plasma samples will be aliquoted into two pre-labeled cryovials for approximately 1 mL in original cryovial and leaving the remaining volume for the duplicate cryovial. Cryovials containing plasma sample will be stored at -70±10 °C.

Analytical Method Sitagliptin and Metformin plasma concentration will be assayed as per international Guidelines/In-house SOP by using a validated LC-MS/MS method.

Pharmacokinetic Parameters Primary pharmacokinetic parameter: Cmax, AUC0→t and AUC0→∞ Secondary pharmacokinetic parameter: Tmax, T1/2, Kel, AUC0→t/AUC0→∞ will be determined from the plasma concentration data of analytes.

Statistical Analysis ANOVA, two one-sided tests for bioequivalence, for log-transformed pharmacokinetic parameters Cmax, AUC0→t and AUC0→∞ will be performed.

Acceptance Criteria for Bioequivalence To be considered as bioequivalent, the 90% Confidence Interval of the geometric means ratio of Cmax, AUC0→t and AUC0→∞ of Sitagliptin and Metformin of test and reference products should be in the interval of 80.00-125.00% for the log-transformed data.

02

Conditions studied

  • Healthy Subjects

Keywords

  • Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg
03

In context

Lead sponsor

Bio-innova Co., Ltd is the lead sponsor of 16 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willingness to provide written prior to participate in the study.
  2. Healthy Thai subjects are between 18 to 55 years of age.
  3. The (BMI) ranges from 18.5 to 30 kg/m2.
  4. Comprehensive of the nature and purpose of the study and compliance with the requirement of the entire protocol and allow investigators to draw 7 mL of blood for monitoring subjects' safety after the completion of the study.
  5. Negative urine pregnancy test for women and no breast-feeding.
  6. Absence of significant diseases or abnormal laboratory values on the laboratory evaluations, medical history or surgery during the screening. Some of the laboratory values e.g. Complete blood count etc. that out of the normal range will be carefully considered by physician.

Exclusion criteria

Exclusion Criteria:

  1. History or evidence of allergy or to Sitagliptin, Metformin or any related drugs or any of the of this product.
  2. Subject with B.P. is Systolic B.P \< 90, ≥140 mm/Hg, Diastolic B.P \< 60, ≥90 mm/Hg, pulse rate > 100 beats per minute.
  3. Serum greater than 1.5 times the upper limit of reference range (ULRR).*
  4. Serum creatinine greater than 1.5 times the upper limit of reference range (ULRR).*
  5. Alanine amino transferase () or aspartate amino transferase (AST) greater than 2 times the upper limit of reference range (ULRR).*
  6. Positive of or C virus.
  7. Have more than one abnormal , which is considered as . *
  8. History or evidence of heart, renal, hepatic disease, pulmonary obstructive disease, bronchial asthma, hypertension or glaucoma
  9. History or evidence of gastrointestinal disorder likely to influence drug absorption or previous GI surgery other than appendectomy.
  10. History or evidence of hypoglycemia before drug administration of each period.*
  11. Any major illness in the past 3 months or any significant ongoing chronic medical illness.
  12. History of psychiatric disorder.
  13. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) and cannot stop at least 2 days before the study drug administration and until the completion of each period of the study.
  14. History of usually smoking (more than 10 cigarettes per day within past 1 year), if moderate smokers (less than 10 cigarettes per day) cannot stop at least 7 days before the study drug administration and until the completion of the study.
  15. High caffeine consumption (more than 5 cups of coffee or tea per day) and cannot stop at least 2 days before the study drug administration and until the completion of each period of the study.
  16. History of grapefruit, pomelo or grapefruit products consumption and cannot stop at least 7 days before the study drug administration and until the completion of the study.
  17. Positive drug abused test in urine (Benzodiazepines, Marijuana (THC), Methamphetamine, Cocaine and Opioids).
  18. Receipt of any prescription drug therapy within 14 days or 5 half-lives (whichever longer) preceding the first dose of study medication or over-the-counter (OTC) drugs or herbal medicines/food supplement within 7 days or hormonal methods of within 28 days (Depo-Provera must be discontinued at least 6 months) prior to the study drug administration and until the completion of each period of the study.
  19. History of difficulty in accessibility of veins in left and right arm.
  20. Blood donation (one unit or 450 mL) within the past 3 months before the study.
  21. Participation in any clinical study within the past 3 months before the study.
  22. Subjects who are unwilling or unable to comply with the lifestyle guidelines described in this protocol.

(* Depend on decision of principal investigator and/or clinical investigator)

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Sequence 1-Sitagliptin and Metformin Hydrochloride Tablets test product

    Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg test product, treatment 2= Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg reference product.

    Drug: Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Test product

  • Experimental
    Sequence 2-Sitagliptin and Metformin Hydrochloride Tablets reference product

    Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg test product, treatment 2= Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg reference product.

    Drug: Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Reference product

Interventions

  • DrugSitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Test product

    Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Manufactured by: Mankind Pharma Limited, India

  • DrugSitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Reference product

    Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Manufactured by: Patheon Puerto Rico, Puerto Rico 00674

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC 0-t)

    pre-dose (0.00 hour) and at 0.333, 0.667, 1.000, 1.500, 2.000, 2.500, 3.000, 3.333, 3.667, 4.000, 4.333, 4.667, 5.00, 5.50, 6.00, 7.00, 8.00, 10.00, 12.00, 24.00, 36.00 and 48.00 hours post-dose

    Time frame: Blood samples will be collected for PK analyses in pre-dose and at 0.333, 0.667, 1.000, 1.500, 2.000, 2.500, 3.000, 3.333, 3.667, 4.000, 4.333, 4.667, 5.00, 5.50, 6.00, 7.00, 8.00, 10.00, 12.00, 24.00, 36.00 and 48.00 hours post-dose

  2. Maximal measured plasma concentration (Cmax)

    pre-dose (0.00 hour) and at 0.333, 0.667, 1.000, 1.500, 2.000, 2.500, 3.000, 3.333, 3.667, 4.000, 4.333, 4.667, 5.00, 5.50, 6.00, 7.00, 8.00, 10.00, 12.00, 24.00, 36.00 and 48.00 hours post-dose

    Time frame: Blood samples will be collected for PK analyses pre-dose (0.00 hour) and at 0.333, 0.667, 1.000, 1.500, 2.000, 2.500, 3.000, 3.333, 3.667, 4.000, 4.333, 4.667, 5.00, 5.50, 6.00, 7.00, 8.00, 10.00, 12.00, 24.00, 36.00 and 48.00 hours post-dose

Secondary outcomes

  1. Number of subjects with adverse events

    An adverse event (AE) is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: Approximately the day 14 after the last visit

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Company Policy

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2024; primary completion for Jul 2024, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2023
First posted
Jan 31, 2024
StartEst.
Jun 4, 2024
Primary completionEst.
Jul 14, 2024
CompletionEst.
Jul 28, 2024
Last update
Jan 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06233201
Lead sponsor
Bio-innova Co., Ltd
Responsible party
Sasitorn Kittivoravitkul (Principal Investigator, Bio-innova Co., Ltd) — Principal investigator
First posted
Jan 31, 2024
Start date
Jun 4, 2024 (estimated)
Primary completion
Jul 14, 2024 (estimated)
Completion
Jul 28, 2024 (estimated)
Last update
Jan 31, 2024

Study contacts

Sasitorn Kittivoravitkul, Ph.D.
Contact
sasitorn_k@bio-innova.com
022549008
Somkiat Tatritorn, M.D.
Contact
somkiat_t@bio-innova.com
022549008

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion